Pevion Launches New Immune Enhancement Platform Called Defensomes

Pevion Launches New Immune Enhancement Platform Called Defensomes PR Newswire ITTIGEN, Switzerland, November 8, 2012 ITTIGEN, Switzerland, November 8, 2012 /PRNewswire/ -- - Patent already granted in Europe - Pevion Biotech AG today announced the launch of a new program called D e f e n s o m e s, a platform for broad spectrum immune enhancement via mechanisms of innate immunity. The proprietary technology is derived from a vaccine platform with a solid safety track record comprising more than 80 million doses applied to humans to date. D e f e n s o m e s offer opportunities for a wide range of prophylactic and therapeutic indications, where boosting of the body's own natural defense is beneficial. "Ways of stimulating the body's own natural defense in a broad manner is not new," says Pevion CEO Evert Kueppers, "however, you need to have a technology capable of doing it in a smart and gentle way. More importantly, you need the safety on your side. That's why Defensomes are particularly well suited for this task." Defensomes are influenza virus-like particles (VLP) that are produced by a commercially validated in vitro process. They act as a subtle activator of innate immunity. This is characterized by a protective effect within a few hours after application, as opposed to adaptive-immunity addressing vaccines, that need a few weeks to develop full protection.